René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined Lundbeck in 2001 and changed to Janssen in 2016. Dr. Holm has worked within pharmaceutical development, formulations for non-clinical testing in drug discovery, physical chemistry and material science covering both small and large molecules and is now responsible for the functional unit ensuring development of all non-solid formulations for Janssens small molecule value stream. Dr. Holm is (co-) author of more than 200 original articles in peer-reviewed journals and patents in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and is a honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark. Dr. Holm is now a Professor at the University of Southern Denmark.
After finishing her studies of Pharmaceutical Sciences at the University of Leipzig, Germany, Sarah Hedtrich completed her PhD in pharmacology & toxicology at the Freie Universität Berlin. During her postdoc she moved to the Ludwig-Maximilians-University in Munich and the Tufts University in Boston, USA. After returning to Berlin, she headed a junior research group from 2013-2015 before she was appointed as an assistant professor in April 2015. Since January 2019, she has been an assistant professor with tenure track at the University of British Columbia, Canada. Her lab combines research expertise in pharmacology, biomedical engineering & drug delivery. They focus on the establishment of Next Generation Therapies, Nanomedicine, Tissue Engineering & Tissue Regeneration. They are particularly interested in healthy and diseased states of human epithelia with a current focus on inflammatory and genetic diseases of the human skin and lung. Sarah is (co-)author of more than 50 original articles in peer reviewed journals in the fields of nanomedicine, drug delivery, skin biology and more.
Dr. Wettig obtained his Ph.D. studying the physical chemistry of novel mixed surfactant/polymer systems with Dr. Ron Verrall in the Department of Chemistry at the University of Saskatchewan. He was appointed Associate Dean of Science for Graduate Studies in October, 2018.Dr. Wettig's research interests lie in the general areas of biophysical chemistry and nanotechnology; in particular at the interface of these two broadly defined areas. This research involves aspects of physical chemistry, solution thermodynamics, biochemistry and cell biology applied to the study of self-assembling systems. Dr. Wettig's research focuses on the design, synthesis and characterization of novel surfactants with an eye toward their application in drug delivery. His current research projects are focused on the study of novel cationic lipid DNA complexes with potential application to genetic therapies, the characterization of novel amino acid derivatives for transdermal drug delivery, and the development of fluorescent surfactants for mechanistic studies.
Gavin Corcoran, MD, serves as Sio Gene Tx’s Chief R&D Officer. In his career, he has overseen successful drug development across multiple therapeutic areas, including neurology and psychiatry, and was previously Chief Medical Officer of Allergan plc and Actavis. Dr. Corcoran was Executive Vice President for Global Medicines Development at Forest Laboratories prior to the acquisition of Forest Laboratories by Actavis. Dr. Corcoran also served as Head of Late Stage Clinical Development for Inflammation and Immunology at Celgene, and as Chief Scientific Officer and Head of R&D at Stiefel Laboratories. Earlier in his career, he held leadership roles in clinical development and regulatory affairs at Amgen, Schering-Plough, and Bayer. He received his MB BCh from the University of the Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.
Roger L. Kaspar, PhD, was the CEO and scientific founder of TransDerm, a company focused on developing novel therapeutics, including inhibitors based on RNA interference (RNAi) technology, for skin disorders (acquired by Allergan). Dr. Kaspar received his doctorate from the University of Washington (Seattle) in biochemistry (David Morris) and performed post-doctoral work at M.I.T. (Lee Gehrke), Stanford University (Helen Blau), and Chiba University (Tomohito Kakegawa). After serving on the faculty at Brigham Young University (Utah) in the Department of Chemistry and Biochemistry, he left academia to work at SomaGenics, prior to founding TransDerm. Drawing on his expertise is in the area of post-transcriptional gene regulation, his current efforts are focused on designing highly potent and selective therapeutic siRNAs that target disease-causing genes in skin disorders, including pachyonychia congenita, and investigating methods to efficiently deliver agents such as siRNAs to appropriate skin cells.
Alasdair is currently a Venture Partner at Luminous Ventures, Ada Ventures (two London based early-stage venture firms), and Mubadala (Emirati Sovereign Wealth Fund), an advisor to KdT Ventures (an Austin, Tx based early-stage VC firm) and Head of Business and Corporate Development for BIOS Health (a UK/US/CAN neural interface and therapeutics company). He was previously a Director in the investment team at Leaps, the disruptive innovation and venture capital arm of Bayer AG, a multinational pharmaceutical, crop science and consumer health conglomerate and was responsible for Huma/Medopad among others, within the Leaps portfolio. He concentrates on the intersection of information technology and life sciences, and holds a particular investment focus on deep tech in life sciences and healthcare, digital health, regenerative medicine and cellular therapies. Alasdair previously held a joint investment/operational (as senior management within invested portfolio companies) role in the life science teams of two leading European venture capital firms, Medicxi and Index Ventures, and completed investments into a number of companies including: Morphogen-IX, Epsilon-3 Bio, Methuselah Health, Z Factor, Padlock Therapeutics and Stealthyx Therapeutics. Alasdair graduated with an undergraduate degree in Law and Mandarin Chinese from the School of Oriental and African Studies, University of London and an MPhil in Bioscience Enterprise from the University of Cambridge. He was also a visiting student at Fudan University (Shanghai) and Beijing Normal University studying Mandarin Chinese.
Dr. Maleek Jamal is a healthcare strategist and implementation leader who helps health systems achieve the Triple Aim by building the system and site-level infrastructure, capacity, and cultural alignment across the care continuum to enable transformation. He began his career in regenerative medicine, earning his doctorate from the Genome Innovation Center at McGill University in Montréal, and went on to cofound a biotechnology company that patented and advanced a new therapy for diabetes. Dr. Jamal then joined and went on to lead the healthcare practice of the Boston Consulting Group where he partnered with boards, CEOs, and business unit leaders from Fortune 100 organizations. His project teams focused on business imperatives for growth and operational turnaround that required both the integration and alignment of organizational resources, and the development of new business units to disrupt markets. Since 2009, Maleek has advanced efforts to measure and improve culture and burnout across US healthcare, delivering consulting and SaaS solutions to more than 1300 hospitals. He has worked closely with executive and clinical leaders from organizations including Mayo Clinic, Kaiser Permanente, the University of California, Alliance Healthcare Services, and the Military Health System to develop and implement high reliability transformations that have created new clinical, operational, and financial value.
Dr. Mamdani is Vice President of Data Science and Advanced Analytics at Unity Health Toronto. Dr. Mamdani’s team bridges advanced analytics including machine learning with clinical and management decision making to improve patient outcomes and hospital efficiency. Dr. Mamdani is also Professor in the Department of Medicine of the Temerty Faculty of Medicine, the Leslie Dan Faculty of Pharmacy, and the Institute of Health Policy, Management and Evaluation of the Dalla Lana Faculty of Public Health. He is also adjunct Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES) and a Faculty Affiliate of the Vector Institute, which is a leading institution for artificial intelligence research in Canada.Dr. Mamdani holds a Doctor of Pharmacy degree from the University of Michigan, a fellowship in pharmacoeconomics from the Detroit Medical Centre, a Master of Arts degree in econometric theory from Wayne State University, and a Master of Public Health from Harvard University with a focus on statistics and epidemiology. He has previously been named among Canada’s Top 40 under 40. Dr. Mamdani’s research interests include pharmacoepidemiology, pharmacoeconomics, drug policy, and the application of advanced analytics approaches to clinical problems and health policy decision-making. He has published over 500 studies in peer-reviewed healthcare journals.“Dr Mamdani founded the Ontario Drug Policy Research Network (ODPRN), the Li Ka Shing Centre for Healthcare Analytics Research and Training (LKS-CHART), and the Applied Health Research Centre (AHRC) at St. Michael’s Hospital.Muhammad is now the director of The Temerty Centre for Artificial Intelligence Research and Education in Medicine (T-CAIREM). Muhammad is Professor at LMP, the Department of Medicine of the Faculty of Medicine, the Leslie Dan Faculty of Pharmacy, and the Institute of Health Policy, Management and Evaluation of the Dalla Lana Faculty of Public Health”